Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
26 Settembre 2024 - 1:30PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced the next
CEO Corner segment has been published on the Company’s
website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix,
addressed Pain Awareness Month and what the Company is doing to
address the significant unmet need in pancreatic cancer pain.
The CEO Corner segment is now
available here.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class platform system technology includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing this technology for
the treatment of pain, with initial trials focused on pancreatic
cancer, a condition that causes debilitating pain and is without a
reliable solution. Our technology constitutes a platform to address
dozens of indications, including cardiology, hypertension and
chronic pain management, across a wide disease spectrum. Our
technology is investigational and has not yet been cleared for
marketing in the United States.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in the CEO Corner video
are “forward-looking statements,” which involve risks and
uncertainties. Forward-looking statements in the CEO Corner video
include, without limitation, the potential of the technology to
treat pain associated with pancreatic cancer, to successfully
enroll patients within the specific timeframe, and to complete its
clinical study in pancreatic cancer pain. Such forward-looking
statements can be identified by the use of words such as “should,”
“might,” “may,” “intends,” “anticipates,” “believes,” “estimates,”
“projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (SEC) on May 31, 2024.
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas908.824.0775autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024